Dr Reddys Laboratories Ltd (DRREDDY) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,271.00",
    "chg": 2,
    "chgp": "0.16%",
    "dir": 1,
    "prev_price": "1,269.00",
    "mcapval": "106,379.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "7.98 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 26.26 vs Industry's 34.62: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4002387",
        "imagepath": "",
        "date": "2026-05-21 09:21:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> at 26.26 stands well below the industry average of 34.62, signalling a valuation discount that is unusual for a large-cap pharmaceutical player. This divergence suggests that the market is pricing in either a moderation in growth expectations or increased risk relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be trading with a more cautious sentiment. <a href=\"ht..."
      },
      {
        "title": "P/E at 26.5 vs Industry's 34.85: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4000457",
        "imagepath": "",
        "date": "2026-05-20 09:20:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in representing the Pharmaceuticals & Biotechnology sector within India’s premier benchmark index. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures its inclusion in numerous index-tracking funds and ETFs. The company’s market capitalisation of ₹1,10,975.99 crores firmly establishes it as a large-cap entity, a status that underpins its influence on index movements and investor sentiment.</p>\n                <p>Being part of the Nifty 50 confers liquidity advantages and often results in increased institutional participation. This dynamic is evident in Dr Reddys Laboratori..."
      },
      {
        "title": "P/E at 26.44 vs Industry's 35.36: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3998509",
        "imagepath": "",
        "date": "2026-05-19 09:20:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E of 26.44, which is approximately 25% below the Pharmaceuticals &amp; Biotechnology industry average of 35.36. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to peers. The sector’s elevated P/E reflects strong earnings expectations, but <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys</a> appears to be valued more cautiously. This valuation gap raises the question — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-7345..."
      },
      {
        "title": "Are Dr Reddys Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-dr-reddys-laboratories-ltd-latest-results-good-or-bad-3989977",
        "imagepath": "",
        "date": "2026-05-13 19:20:36",
        "description": "Dr. Reddy's Laboratories Ltd. has reported significant operational challenges in its latest financial results for Q4 FY26. The company experienced a notable contraction in its operating margins, which fell to 5.09%, marking the lowest level in recent history. This decline is particularly concerning as it represents a sharp drop from 23.49% in the same quarter last year and 21.63% in the previous quarter. \n\nThe revenue for Q4 FY26 was recorded at ₹7,546.40 crores, reflecting a sequential decline of 13.79% and an 11.51% decrease year-on-year. This marks the first instance of double-digit revenue contraction for Dr. Reddy's in several years, raising questions about the sustainability of its business model under current market conditions. \n\nNet profit for the quarter stood at ₹220.90 crores, which is an 86.14% decline compared to the previous year. The operating profit before depreciation, interest, tax, and ot..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Opens 3.93% Lower in Sharp Gap Down as Technicals Point to Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-opens-with-weak-start-significant-gap-down-amid-market-concerns-3989495",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_gapdown_3989495.png",
        "date": "2026-05-13 11:15:22",
        "description": ""
      },
      {
        "title": "Dr Reddys Laboratories Ltd Reports Sharp Decline in Quarterly Financial Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-reports-sharp-decline-in-quarterly-financial-performance-3988377",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_fintrenddot_3988377.png",
        "date": "2026-05-13 08:00:16",
        "description": "Dr Reddys Laboratories Ltd has reported a significant deterioration in its financial performance for the quarter ended March 2026, with key metrics such as net sales, operating profit, and earnings per share hitting multi-quarter lows. The pharmaceutical giant’s financial trend score plunged from -11 to a very negative -27, signalling mounting challenges in revenue growth and margin sustainability amid rising interest costs and subdued profitability."
      },
      {
        "title": "P/E at 19.38 vs Industry's 34.29: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-3984985",
        "imagepath": "",
        "date": "2026-05-11 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discounted P/E Amid Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 19.38, markedly below the Pharmaceuticals &amp; Biotechnology industry average of 34.29. This represents a discount of approximately 43.5%, suggesting the market is pricing in either a more conservative growth outlook or risk factors not fully reflected in sector valuations. Such a valuation gap invites scrutiny — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a>’s earnings profile and growth trajectory must be analysed carefully to understand whether this discount is justi..."
      },
      {
        "title": "P/E at 19.59 vs Industry's 34.54: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3981017",
        "imagepath": "",
        "date": "2026-05-08 09:21:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E ratio of 19.59 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands in stark contrast to the industry average of 34.54, signalling a valuation discount of nearly 43%. This divergence suggests the market is pricing in either a more conservative growth outlook or perceived risks relative to peers. Such a discount is notable given the company’s large-cap status and established presence in the Pharmaceuticals & Biotechnology sector. The sector itself commands a premium valuation, reflecting robust earnings growth expectations and defensive qualities amid market volatility. <a href=\"https://www.marketsmojo..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Rallies 3.35% and Approaches 5-Day Moving Average Resistance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-high-with-335-surge-on-6-may-2026-3977932",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_priceRelatedfactors_3977932.png",
        "date": "2026-05-06 13:15:56",
        "description": "The Sensex declined by 0.17% on 6 Jun 2026, while Dr Reddys Laboratories Ltd surged 3.35%, outperforming its Pharmaceuticals &amp; Biotechnology sector by 1.08 percentage points. This strong single-session gain marks a notable rebound after four consecutive days of decline, raising the question of whether this is a genuine recovery or a technical bounce within a broader trend."
      }
    ],
    "total": 15,
    "sid": "734514",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "13-Jun-2026",
      "details": "Press Release - Launch of Bosutinib Tablets 400mg.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "12-Jun-2026",
      "details": "Copies of newspaper publication",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "10-Jun-2026",
      "details": "Intimation of analyst meet",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 26.26 vs Industry's 34.62: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-21 09:21:09

Valuation Picture: Discount Amidst Sector Premiums The current P/E ratio of Dr Reddys Laboratories Ltd at 26.26 stands well below the industry average of 34.62, signalling a valuation discount that is unusual for a large-cap pharmaceutical player. This divergence suggests that the market is pricing in either a moderation in growth expectations or increased risk relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet Dr Reddys Laboratories Ltd appears to be trading with a more cautious sentiment. <a href="ht...

P/E at 26.5 vs Industry's 34.85: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-20 09:20:59

Significance of Nifty 50 Membership As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in representing the Pharmaceuticals & Biotechnology sector within India’s premier benchmark index. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures its inclusion in numerous index-tracking funds and ETFs. The company’s market capitalisation of ₹1,10,975.99 crores firmly establishes it as a large-cap entity, a status that underpins its influence on index movements and investor sentiment. Being part of the Nifty 50 confers liquidity advantages and often results in increased institutional participation. This dynamic is evident in Dr Reddys Laboratori...

P/E at 26.44 vs Industry's 35.36: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-19 09:20:47

Valuation Picture: Discount Amidst Sector Premiums Dr Reddys Laboratories Ltd trades at a P/E of 26.44, which is approximately 25% below the Pharmaceuticals & Biotechnology industry average of 35.36. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to peers. The sector’s elevated P/E reflects strong earnings expectations, but Dr Reddys appears to be valued more cautiously. This valuation gap raises the question — <a href="https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-7345...

Are Dr Reddys Laboratories Ltd latest results good or bad?

2026-05-13 19:20:36

Dr. Reddy's Laboratories Ltd. has reported significant operational challenges in its latest financial results for Q4 FY26. The company experienced a notable contraction in its operating margins, which fell to 5.09%, marking the lowest level in recent history. This decline is particularly concerning as it represents a sharp drop from 23.49% in the same quarter last year and 21.63% in the previous quarter. The revenue for Q4 FY26 was recorded at ₹7,546.40 crores, reflecting a sequential decline of 13.79% and an 11.51% decrease year-on-year. This marks the first instance of double-digit revenue contraction for Dr. Reddy's in several years, raising questions about the sustainability of its business model under current market conditions. Net profit for the quarter stood at ₹220.90 crores, which is an 86.14% decline compared to the previous year. The operating profit before depreciation, interest, tax, and ot...

Dr Reddys Laboratories Ltd Opens 3.93% Lower in Sharp Gap Down as Technicals Point to Mixed Signals

2026-05-13 11:15:22

Dr Reddys Laboratories Ltd Reports Sharp Decline in Quarterly Financial Performance

2026-05-13 08:00:16

Dr Reddys Laboratories Ltd has reported a significant deterioration in its financial performance for the quarter ended March 2026, with key metrics such as net sales, operating profit, and earnings per share hitting multi-quarter lows. The pharmaceutical giant’s financial trend score plunged from -11 to a very negative -27, signalling mounting challenges in revenue growth and margin sustainability amid rising interest costs and subdued profitability.

P/E at 19.38 vs Industry's 34.29: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-11 09:20:50

Valuation Picture: Discounted P/E Amid Sector Premiums Dr Reddys Laboratories Ltd trades at a P/E multiple of 19.38, markedly below the Pharmaceuticals & Biotechnology industry average of 34.29. This represents a discount of approximately 43.5%, suggesting the market is pricing in either a more conservative growth outlook or risk factors not fully reflected in sector valuations. Such a valuation gap invites scrutiny — Dr Reddys Laboratories Ltd’s earnings profile and growth trajectory must be analysed carefully to understand whether this discount is justi...

P/E at 19.59 vs Industry's 34.54: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-08 09:21:06

Valuation Picture: Discount Amidst Sector Premiums The current P/E ratio of 19.59 for Dr Reddys Laboratories Ltd stands in stark contrast to the industry average of 34.54, signalling a valuation discount of nearly 43%. This divergence suggests the market is pricing in either a more conservative growth outlook or perceived risks relative to peers. Such a discount is notable given the company’s large-cap status and established presence in the Pharmaceuticals & Biotechnology sector. The sector itself commands a premium valuation, reflecting robust earnings growth expectations and defensive qualities amid market volatility. <a href="https://www.marketsmojo...

Dr Reddys Laboratories Ltd Rallies 3.35% and Approaches 5-Day Moving Average Resistance

2026-05-06 13:15:56

The Sensex declined by 0.17% on 6 Jun 2026, while Dr Reddys Laboratories Ltd surged 3.35%, outperforming its Pharmaceuticals & Biotechnology sector by 1.08 percentage points. This strong single-session gain marks a notable rebound after four consecutive days of decline, raising the question of whether this is a genuine recovery or a technical bounce within a broader trend.

View All News